Asia Fresh News

Asia Fresh Stories

Archive for September 29th, 2014

Putting the Patient First: Merck Serono to Present Data That Embodies the ESMO 2014 Theme of ‘Precision Medicine in Cancer Care’ DARMSTADT, Germany, September 26, 2014/PRNewswire/ —

leave a comment »

DARMSTADT, Germany  /PRNewswire/ —

Not intended for US- and UK-based media

ESMO 2014 Abstract #: Physician biomarker survey: 1080O_PR; Erbitux: CRYSTAL: 541P; LASCCHN: 993PD; DIRECT: 996P; Pipeline: pimasertib: 443O; c-Met: 1333TiP, 450PD, 744TiP, 745TiP; further pipeline: 772P, 507PD, 1235P

  • New research evaluates physicians’ understanding of predictive biomarkers and perceptions of what patients themselves understand about personalized medicine
  • Key data from analyses of Erbitux® (cetuximab) in RAS wild-type metastatic colorectal cancer and in human papillomavirus p16+/p16- locoregionally advanced SCCHN patient populations
  • Pipeline data on early-stage compounds targeting specific pathways in difficult-to-treat cancers

Merck Serono, the biopharmaceutical division of Merck, today announced that it will be presenting data at the European Society for Medical Oncology (ESMO) 2014 congress (Madrid, Spain, September 26-30, 2014) aligned with the congress theme of ‘Precision Medicine in Cancer Care’. ‘Precision medicine’, as defined by ESMO 2014, involves providing optimal treatment for patients according to their individual circumstances and the molecular characteristics of their disease.[1]

“Merck Serono believes in the principle of ‘Precision Medicine’; it underpins both our patient-centric approach and our commitment to identifying those patients who would benefit most from our medicines,” said Luciano Rossetti, Head of Research and Development, Merck Serono. “The data at ESMO 2014 demonstrates how we put the patient first, and go beyond treatment to support the delivery of focused cancer care, including biomarker testing.”

Physician and Patient Understanding of Biomarkers

Findings from a Merck Serono-sponsored global survey of oncologists (n=895)[2] from 12 countries (across Asia,Europe and South America) on their use of predictive biomarkers in a range of late-stage and metastatic cancers (lung, breast and colorectal [mCRC]) will be presented during an oral session on Sunday, September 28, 11:00-12:20. The survey also includes physician perceptions of patient understanding of biomarkers and treatment options.

Results from the survey will also be included in an official ESMO 2014 press release and are under strict embargo until 11:00 CET on Sunday, September 28, 2014.

Exploring Biomarkers in mCRC and SCCHN

Retrospective subanalyses from two pivotal Phase III studies for Erbitux® (cetuximab) will be presented as part of Merck Serono’s continued effort to further understand biomarkers that may help to inform treatment decisions. The CRYSTAL* study subanalysis evaluates Erbitux plus FOLFIRI (folinic acid, 5-fluorouracil and irinotecan), compared with FOLFIRI alone, in patients with RAS wild-type mCRC, as assessed by liver-limited disease (LLD) status. Further data from the Bonner study assesses the prognostic value of p16 status (p16 positive and p16 negative), a marker of human papillomavirus, in patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN).

Pipeline Data: Targeting Specific Pathways

Merck Serono is presenting data from its diversified early-stage pipeline at ESMO 2014, underscoring the importance of targeting specific pathways. Data include results in difficult-to-treat cancers, as well as in specific patient populations. Highlights include: an oral presentation on results from a Phase Ib study of pimasertib, a MEK inhibitor, in selected genotype-defined solid tumors; pimasertib in combination with SAR245409, a PI3K/MTOR inhibitor; and a number of studies of the highly selective c-Met inhibitor MSC2156119J (EMD 1214063), including a poster discussion of the first-in-human Phase I results in patients with advanced solid tumors. Data will also be presented on abituzumab (DI17E6, EMD 525797) an investigational anti-integrin monoclonal antibody.

Notes to Editors

Abstracts related to Merck Serono studies with Erbitux and pipeline compounds include:


Title: FOLFIRI plus cetuximab in patients liver-limited or non-liver-limited RAS wild-type metastatic disease: A sub-group analysis of the CRYSTAL study
Lead author: C-H Kohne
Abstract #: 541P
Presentation date/time (CET): Sep 29, 12:45–13:45
Session: Poster Display Session
Room/details: Poster display area

Title: Association of human papillomavirus (HPV) and p16 status with efficacy and safety data in the Phase III radiotherapy (RT)/cetuximab (cet) registration trial for locoregionally advanced squamous cell carcinoma of the head and neck (LASCCHN)
Lead author: JA Bonner
Abstract #: 993PD
Presentation date/time (CET): Sep 28, 13:00–14:00
Session: Poster Discussion, Head and Neck Cancer
Room/details: Bilbao

Title: Cetuximab relative dose intensity (RDI) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First observational prospective study in unselected patients (DIRECT trial)
Lead author: J Guigay
Abstract #: 996P
Presentation date/time (CET): Sep 29, 12:45–13:45
Session: Poster Display Session
Room/details: Poster display area

General oncology: Physician biomarker survey

Title: Physicians’ awareness and understanding of personalized medicine in the treatment of cancer and its adoption in clinical practice: a multinational survey
Lead author: F Ciardiello
Abstract #: 1080O_PR
Presentation date/time (CET): Sep 28, 11:00–12:20
Session: Proffered Papers, Issues Facing Oncologists Today
Room/details: Alicante

c-Met inhibitor, MSC2156119J

Title: Phase Ib/II trial of c-Met inhibitor MSC2156119J and gefitinib vs chemotherapy as 2nd-line treatment in Asian patients with Met-positive (Met+), locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor mutation (EGFRm+) and progression on gefitinib
Lead author: K Park
Abstract #: 1333TiP
Presentation date/time (CET): Sep 27, 12:45–13:45
Session: Poster Display Session
Room/details: Poster display area

Title: First-in-human Phase I trial assessing the highly selective c-Met inhibitor MSC2156119J (EMD 1214063) in patients with advanced solid tumors
Lead author: GS Falchook
Abstract #: 450PD
Presentation date/time (CET): Sep 28, 13:00–14:00
Session: Poster Discussion Session, Developmental Therapeutics
Room/details: Alicante

Title: Met-positive advanced hepatocellular carcinoma and Child-Pugh class A liver function in Asian patients: a randomized, multicenter, Phase Ib/II trial of the oral c-Met inhibitor MSC2156119J vs sorafenib
Lead author: S Qin
Abstract #: 744TiP
Presentation date/time (CET): Sep 29, 12:45–13:45
Session: Poster Display Session
Room/details: Poster display area

Title: Phase Ib/II, multicenter, single-arm trial of the oral c-Met inhibitor MSC2156119J as monotherapy in patients with Met-positive advanced hepatocellular carcinoma with Child-Pugh class A liver function who failed sorafenib treatment
Lead author: S Faivre
Abstract #: 745TiP
Presentation date/time (CET): Sep 29, 12:45–13:45
Session: Poster Display Session
Room/details: Poster display area

Pimasertib, a MEK inhibitor

Title: Pimasertib (PIM) and SAR245409 (SAR) – a MEK and PI3K/MTOR inhibitor combination: A Phase Ib trial with expansions in selected genotype-defined solid tumors
Lead author: RS Heist
Abstract #: 443O
Presentation date/time (CET): Sep 27, 14:00–15:45
Session: Proffered Papers, Developmental Therapeutics, Oral Presentation
Room/details: Cordoba

Additional Pipeline Projects: Oncology

Title: Abituzumab (DI17E6, EMD 525797) treatment for chemotherapy-naive patients with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC): primary outcomes of the placebo-controlled Phase 2 study PERSEUS (NCT01360840)
Lead author: K Miller
Abstract #: 772P
Presentation date/time (CDT): Sep 27, 12:45–13:45
Session: Poster Display Session
Room/details: Poster display area

Title: POSEIDON Phase I/II trial: abituzumab combined with cetuximab plus irinotecan as second-line treatment for patients with KRAS wild-type metastatic colorectal cancer
Lead author: E Élez
Abstract #: 507PD
Presentation date/time (CDT): Sep 27, 13:00–14:00
Session: Poster Discussion Session, Gastrointestinal Tumors, Colorectal
Room/details: Granada

All early-stage products are currently under clinical investigation and have not been approved for use in the U.S.,Europe, Canada, or elsewhere. All investigational products have not yet been proven to be either safe or effective and any claims of safety and effectiveness can be made only after regulatory review of the data and approval of the labeled claims.

*CRYSTAL: Cetuximab combined with iRinotecan in first-line therapY for metaSTatic colorectAL cancer


  1. European Society for Medical Oncology 2014 Congress Page. Available at: Last accessed September 2014.
  2. Ciardiello, F et al. Oral presentation at the European Society for Medical Oncology Congress, 2014,September 28. Abstract No:1080O_PR.

For more information on Merck Serono in oncology and immuno-oncology, please visit:

About Erbitux

Erbitux® is a first-in-class and highly active IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of Erbitux is distinct from standard non-selective chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth.

The most commonly reported side effect with Erbitux is an acne-like skin rash that seems to be correlated with a good response to therapy. In approximately 5% of patients, hypersensitivity reactions may occur during treatment with Erbitux; about half of these reactions are severe.

Erbitux has already obtained market authorization in over 90 countries for the treatment of colorectal cancer and for the treatment of squamous cell carcinoma of the head and neck (SCCHN).

Merck licensed the right to market Erbitux outside the US and Canada from ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, in 1998. In Japan, ImClone, Bristol-Myers Squibb Company and Merck jointly develop and commercialize Erbitux. Merck has an ongoing commitment to the advancement of oncology treatment and is currently investigating novel therapies in highly targeted areas.

About Merck Serono

Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.

For more information, please visit

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to to register online, change your selection or discontinue this service.

Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of our customers and to help meet global challenges.

Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day.

Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions areCanada and the United States, where the company is known as EMD.

Source: Merck Serono

Written by asiafreshnews

September 29, 2014 at 5:15 pm

Posted in Uncategorized

EMMY Nomination for Alexis Nelson of HOAX Films

leave a comment »

LOS ANGELES /PRNewswire/ — Alexis Nelson, Owner and Executive Producer of HOAX Films, aLos Angeles, California and Savannah, Georgia digital production studio, is nominated for an EMMY forOutstanding Graphic Design & Art Direction for “Ultimate Guide to the Presidents”, produced by (Executive Producers) Karga Seven Pictures for The History Channel. The Gala will be held September 30, 2014 at New York City’s Lincoln Center.

Photo –
Photo –
Photo –

“Ultimate Guide to the Presidents” is an eight-hour miniseries that follows the 43 men who have served as President of the United States, using extensive historical documentation including archival footage and photographs. With creative imagery and animation, the show illustrates the responsibilities, events, challenges, and feats of these America’s leaders. The graphics were created under the direction of Production Company Karga 7, and Producer Fikret Manoglu.

“This is a huge honor,” says Nelson. “We wanted to try a new take on bringing history to life that makes it more understandable and visually appealing. A combination of 2D and 3D processes allowed us to pull historical documents and imagery apart, then animate them, creating narrative stories while keeping the integrity of the sources.

I’m thrilled that the distinctive style and graphics are being recognized. This is a great start for HOAX’s current expansion of integrating development and production into our current post production pipeline.”

Although this would be their first EMMY, their film production, CG and VFX efforts on the futuristic website, MEBO Campus ( have lead to a plethora of recognition, including six Davey Awards, six W3 Awards, four Communicator Awards, two IAC Awards and an Interactive Media Award.

MEBO Campus was developed under Kevin Xu’s direction, the entrepreneurial CEO of MEBO International, a company exclusively focused on managing the intellectual properties of organ regeneration science related to its founder, Dr. Rongxiang Xu. The aim of the website is to educate the Western world about the wonders of organ regeneration science through experience.

HOAX Films is a digital production studio known for it’s work on campaigns for Game of Thrones, Harry Potter 7, feature films like Fast 5, Zombeavers, Spike TV’s Deadliest Warrior, and music videos for Katy Perry, Britney Spears, Little Dragon, and Absolut Vodka. HOAX is partnered with Fort Argyle Films and is in development on TV series Double Wide Blues and feature film A Savannah Haunting.


Source: HOAX Films

Written by asiafreshnews

September 29, 2014 at 5:03 pm

Posted in Uncategorized

PM to Open Cambodia’s International Investment Conference 2014

leave a comment »

PHNOM PENH, Cambodia, Sept. 23, 2014 /PRNewswire/ — Cambodia’s Prime Minister Akka Moha Sena Padei Techo Hun Sen will officially open the country’s premier international investment conference in Phnom Penh next month (October), according to the event’s organisers, the International Business Chamber of Cambodia (IBC).

The event, which will take place on October 6th and 7th at the Intercontinental Hotel in Phnom Penh, is expected to attract hundreds of overseas companies with an interest in investing in Cambodia. The conference, which takes place once every two years, is the 8th International Investment Conference sponsored by the IBC.

The conference is expected to be the biggest business event of its kind to be held in Cambodia in 2014. It is being held under the banner “Cambodia – a new era of opportunity.” A sub-theme of the conference will be “Growth, Change and ASEAN Integration.”

The purpose of the IBC-organised event is to attract the attention and participation of some of the region’s most influential captains of industry and business leaders. The IBC is also aiming to “turn the spotlight on Cambodia as a desirable country for international companies to invest.” Integration into the ASEAN Economic Community will also be a theme.

Cambodia’s impressive growth is encouraging more and more companies to look at Cambodia as a place to set up their business or to expand their reach,” said IBC Chairman Brett Sciaroni.

Topics for discussion at the event will include Cambodia‘ economic outlook as well as the country’s competitiveness. ASEAN integration will also be a theme.

Platinum sponsors for the IBC conference are Prudential Cambodia, Jardine Matheson Limited, Sciaroni and Associates, ACLEDA Bank and ANZ Royal.

Gold sponsors include DFDL and Ezecom.

HongKong Land is sponsoring the event’s golf social. RMAsia is a transportation sponsor.

The South East Asia Globe and its sister publication Focus ASEAN are media partners of the event.

Please visit for further details about the IBC and the conference.

Please contact Glen Felgate on +855-12-800966 for further information.

Source: The International Business Chamber of Cambodia (IBC)

Written by asiafreshnews

September 29, 2014 at 5:03 pm

Posted in Uncategorized

Access Control Integrations Handle Physical Security from the Easy-to-Use Milestone XProtect Video Interface

leave a comment »

COPENHAGEN, Denmark /PRNewswire/ —

Industry trade shows in the U.S. and Europe showcase the new interoperable IP solutions

Milestone Systems open platform IP video management software (VMS) integrated with access control systems from multiple Milestone Solution Partners will be presented at this month’s security industry events: SECURITY Essen in Germany and ASIS International in Atlanta, Georgia.

(Logo: )

Numerous Milestone Solution Partners are using the new XProtect® Access Control Module 2014 to offer unified integrations of their access control systems into Milestone XProtect® video surveillance solutions. The ability to tie video and access events together in this way greatly improves the speed and efficiency of incident investigations and response.

Providing the primary and most commonly used access control functions as an integral part of the XProtect® Smart Client interface, the Milestone XProtect Access Control Module 2014 eliminates the need for users to work with disparate independent systems. It also makes it possible to integrate different access control systems within the same XProtect customer installation.

The XProtect Smart Client provides the consolidated interface for operating integrated access control systems with such dedicated functions as monitoring access events with video verification, manually assisting passages (controlling doors, gates, etc.), conducting investigations of specific access points or cardholders, easily exporting video evidence and generating reports. Video of access incidents visually confirms and informs on situations as they happen for better response, and provides documentation for analysis, rectification or prosecution.

The Milestone partner ecosystem worldwide is teeming with more than thirty integrations of access control systems with the Milestone video platform, to fill market demands for this kind of solution. Many of these are achieved using the XProtect Access Control Module 2014, being presented here:

SECURITY Essen – September 23-26
Axis: Hall 2, Milestone stand 216 and Axis stand 311 and 507
Bosch Security Systems: Hall 2, Milestone stand 216 and Bosch stand 216
KABA: Hall 3, Kaba stand 310
Suprema/Camsecure: Hall 5, Suprema stand 134
AxessTMC (Zucchetti Group): Hall 2, Milestone stand 216

ASIS International – September 29-October 1
Axis: Axis booth 1023 and Anixter booth 1016
Bosch Security Systems: Bosch booth 3237
IMRON: Axis booth 1023 and Anixter booth 1016
ISONAS: Milestone booth 1043
Open Options: Open Options booth 2455
Siemens Building Technologies: Siemens booth 2525

Of these access control Milestone Solution Partners, ISONAS is the first to get certification on their ISONAS ACXintegration using the XProtect Access Control Module. This means that the integrated solution with their pure-IP access control that is operable from within the XProtect Smart Client interface has been tested and proven for best-practice implementation and documented with optimized configurations.

“Milestone XProtect now has the ability to handle both video and access control. The ISONAS-Milestone integration allows customers to seamlessly deploy access control with the same topology as their cameras. This eliminates the need for additional power at the door, resulting in dramatically lower cost-of-ownership, providing a more flexible and scalable solution while avoiding the need to re-train Milestone XProtect users. This integration has the ability to dramatically change the way video and access control are implemented and managed with best-in-class video as the front-end,” says Rob Mossman, CEO at ISONAS.

Axis Communications is also entering the physical access control market by introducing in Europe a network door controller with built-in web-based software. AXIS A1001 Network Door Controller is a complement to the existing Axis portfolio of innovative network video products and creates unique integration possibilities for partners and end users, including interoperability via the Milestone XProtect Access Control Module 2014.

“By leveraging the embedded functionality of AXIS Entry Manager, Milestone XProtect Access Control Module plays an important role in integrating visual validation of controlled door passage with the AXIS A1001 Network Door Controller,” said Johan Lembre, Director, Global Sales Solution, Enterprise & Medium Business, Axis Communications.

XProtect Access Control Module 2014 is part of the Milestone Integration Platform Software Development Kit (MIP SDK), available through Milestone channel partners. This will be presented by Milestone Systems at Security Essen (Hall 2, Milestone stand 216) and ASIS International (Milestone booth 1043). The integrations with the access control systems from Milestone Solution Partners are available through their respective sales channels.

About Milestone Systems
Milestone Systems is a global industry leader in open platform IP video management software, founded in 1998 and now operating as a stand-alone company in the Canon Group. Milestone technology is easy to manage, reliable and proven in thousands of customer installations, providing flexible choices in network hardware and integrations with other systems. Sold through partners in more than 100 countries, Milestone solutions help organizations to manage risks, protect people and assets, optimize processes and reduce costs. For more information, please visit:

Source: Milestone Systems

Written by asiafreshnews

September 29, 2014 at 5:00 pm

Posted in Uncategorized

Integration Potential of Electric Parking Brakes Drives their Adoption in China, Finds Frost & Sullivan

leave a comment »

— Currently confined to the premium segment, EPB systems are expected to trickle down to economy and non-premium segments by 2021

SHANGHAI /PRNewswire/ — The influx of world-class vehicles in the Chinese passenger vehicle space along with the rising purchasing power of Chinese consumers is propelling the electric parking brakes (EPB) market in the country. The integration potential of EPB systems with electronic stability control and advanced driver assistance systems will further steer EPB uptake.

New analysis from Frost & Sullivan, Analysis of the Chinese Market for Electric Parking Brakes, expects the market to register a compound annual growth rate (CAGR) of 13.3 percent to reach over €257.9 million in 2021. Unit sale volumes will near the 7 million mark. The non-premium vehicle segment is likely to account for two of every three Euros spent on EPB. Multi-purpose and B segment vehicle segments, in particular, will record a CAGR of more than 40 percent. The caliper integrated EPB is likely to be the most preferred, while the cable puller EPB is expected to witness five-fold growth in terms of volume uptake.

“Despite low awareness among consumers on the benefits of EPB systems, diligent efforts by OEMs to educate end users on state-of-the-art convenience features is paving the way for EPB adoption in China,” said Frost & Sullivan Automotive and Transportation Research Analyst Kamalesh Mohanarangam. “OEMs are also pressurizing suppliers to develop low-cost EPB systems to cater to the price-sensitive Chinese passenger car market.”

Even if Chinese OEMs offer EPB on rebadged vehicle models from their global OEM joint-venture partners, it is highly improbable that consumers will purchase bolt-on EPB options despite the decreased domestic cost of ownership. This is perhaps because buyers tend to opt for such optional packages based on brand equity and the aura of exclusivity that can be associated with premium brands. This aura will be missing from lower-priced domestic offerings.

“Hence, global suppliers must innovate with product lines engineered to suit both ends of the spectrum, covering low-cost Chinese vehicle platforms and top-of-the-line premium vehicles,” advised Mohanarangam. “This will also insulate their product lines from being imitated by competitors or market miscreants.”

To that end, global suppliers are actively investing to expand their operations as they recognize the immense potential for EPB in the country. Global OEMs and their local partners will account for 85 percent of EPB sales in 2021 in the competitive Chinese market.

If you are interested in more information on this study, please send an e-mail to Julie Zheng, Corporate Communications, at

Analysis of the Chinese Market for Electric Parking Brakes is part of the Automotive & Transportation( Growth Partnership Service program. Frost & Sullivan’s related studies include: Commercial Vehicle Telematics Market in China, Chinese Market for Passenger Car Advanced Driver Assistance Systems, and 2014 Automotive Outlook for China. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on “the next big thing”
Register: Gain access to visionary innovation

Analysis of the Chinese Market for Electric Parking Brakes

Julie Zheng
Corporate Communication  — China
P: +86.21.5407.5780 ext. 8698

Source: Frost & Sullivan

Written by asiafreshnews

September 29, 2014 at 2:55 pm

Posted in Uncategorized

Frost & Sullivan: Government Initiatives to Strengthen Demand for Telematics in Commercial Vehicles in China

leave a comment »

— Partnerships with local players will help participants ease the telematics’ cost burden on fleet owners

SHANGHAI /PRNewswire/ — While the ability of telematics to improve operations is undisputed, the technology has been slow to take off in the Chinese commercial vehicle market due to high prices. Nevertheless, government regulations and the technology’s fuel efficiency features are proving to be a strong pull for numerous commercial vehicle operators, giving telematics solution providers in China a reason to feel optimistic.

New analysis from Frost & Sullivan, Strategic Analysis of Commercial Vehicle Telematics Market in China, finds that commercial vehicle and fleet operators’ spending on telematics will surge over the next seven years, till 2021.

The Chinese Government’s initiatives mandating the installation of satellite positioning and telematics systems in specific commercial vehicles bode well for the telematics market. Besides, the fuel efficiency of China’s commercial vehicles is lower than that of the trucks in the Organization for Economic Cooperation and Development (OECD) countries; this concern has further fuelled the uptake of fleet management solutions such as telematics.

“Apart from the high prices of telematics, which are often equivalent to a small fleet operator’s profits, the varied policies of local governments on commercial vehicles also peg back adoption rates,” said Frost & Sullivan Automotive & Transportation Research Analyst Will Wong. “While changes in the regulatory framework are unlikely, varied local governments’ requirements will be a long-term challenge as they complicate the business of fleets.”

Currently, tourist buses, coaches, dangerous goods vehicles, tractor units, and heavy duty trucks are identified by the Chinese Government as the focal commercial vehicles for installing telematics. These vehicles are required to have factory-installed satellite positioning equipment and telematics control units while entering certain provinces. The need to improve the monitoring and management of these types of vehicles presents a huge opportunity for telematics suppliers in the commercial vehicle market.

Participants can also resolve the cost issue to some extent through partnerships with well-developed local participants. Although local partnership is not required, partnering with established local companies will lower the entry barriers.

“The market will open up for telematics providers that have the flexibility to offer customized solutions,” noted Wong. “In a market marked by cost consciousness, meeting the budgets of various scales of fleet operators is vital for success.”

If you are interested in more information on this study, please send an email to Julie Zheng, Corporate Communications, at

Strategic Analysis of Commercial Vehicle Telematics Market in China is part of the Automotive & Transportation ( Growth Partnership Service program. Frost & Sullivan’s related studies include: 2014 Automotive Outlook for China, North American Off-highway Vehicle (OHV) Telematics Market, Commercial Vehicle Telematics Market in Australia, Impact Analysis of In-vehicle Advertising in the North American Automotive Infotainment Market, Automotive Connected Services Market in Brazil and Mexico, and Analyzing the Potential of the Luxury Vehicle Market in India. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on “the next big thing”
Register: Gain access to visionary innovation

Strategic Analysis of Commercial Vehicle Telematics Market in China

Julie Zheng
Corporate Communication China
P: +86.21.5407.5780 ext. 8698

Source: Frost & Sullivan

Written by asiafreshnews

September 29, 2014 at 2:52 pm

Posted in Uncategorized

Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA(R) (edoxaban) in Japan

leave a comment »

TOKYO /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it received approval from the Ministry of Health, Labour and Welfare in Japan for LIXIANA® (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban) for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism].

LIXIANA was approved in Japan in April 2011, for the prevention of VTE after major orthopedic surgery and was launched in July 2011.1 Daiichi Sankyo has also filed for approval of once-daily edoxaban in both the U.S. and EU for the prevention of stroke in NVAF and for symptomatic VTE in patients with DVT and/or pulmonary embolism (PE).2, 3

About Atrial Fibrillation
Atrial fibrillation (AF) is a condition in which the heartbeat is rapid and irregular, and can potentially lead to a stroke.4 AF is a common condition, affecting approximately 2.3-3.4% of people in developed nations.5 AF affects approximately 6 million people in the EU,6 approximately 6.1 million people in the U.S.,7 approximately 1.5 million people in Brazil,8 and more than 800,000 people in Japan.9 Stroke due to all causes is the second most common cause of death worldwide, responsible for approximately 6.2 million deaths each year.10 Compared to those without AF, people with the arrhythmia have a 3-5 times higher risk of stroke.5 Strokes due to AF are nearly twice as likely to be fatal than strokes in patients without AF at 30 days11 and have poorer prognosis than non-AF related strokes, with a 50% increased risk of remaining disabled at three months.12

About Venous Thromboembolism
VTE is an umbrella term for two conditions, DVT and PE. DVT is a blood clot found anywhere in the deep veins of the legs, while PE occurs when part of a clot detaches and lodges in the pulmonary arteries, causing a potentially fatal condition.13 VTE is a major cause of morbidity and mortality worldwide with an annual incidence estimated at one per 1,000 (with some age and regional variation).14 In Japan, there is an estimated annual incidence of 0.19% for DVT and 0.05% for PE.15 In the EU, it is estimated that 430,000 PE events, 680,000 DVT events and 540,000 deaths occur each year.16 In the U.S., it is estimated that more than 950,000 VTE events and approximately 300,000 VTE related deaths occur each year.17,18

About Edoxaban
Edoxaban is an investigational, oral, once-daily anticoagulant that specifically inhibits factor Xa, which is an important factor in the coagulation system that leads to blood clotting.19 The global edoxaban clinical trial program includes two phase 3 clinical studies, Hokusai-VTE and ENGAGE AF-TIMI 48 (Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation), which included nearly 30,000 patients combined. The results from these trials form the basis of regulatory filings for edoxaban for symptomatic VTE in patients with DVT and/or PE, and for the prevention of stroke in NVAF, respectively.20,21 Edoxaban is currently under regulatory review in the U.S. and EU for these indications.

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, dyslipidemia and bacterial infections used by patients around the world, the Group has also launched treatments for thrombotic disorders and is building new product franchises. Furthermore, Daiichi Sankyo research and development is focused on bringing forth novel therapies in oncology and cardiovascular-metabolic diseases, including biologics. The Daiichi Sankyo Group has created a “Hybrid Business Model,” to respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit:

Michaela Paudler-Debus, PhD
+49 89 7808 685 (office)
+49 176 11780966 (mobile)

Teiichiro Koga, PhD
+81 3 6225 1126 (office)

Forward-looking statements
This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO Co., Ltd. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO Co., Ltd. assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.


  1. Daiichi Sankyo press release – Daiichi Sankyo launches LIXIANA® (edoxaban), a direct oral factor Xa inhibitor, in Japan for the prevention of venous thromboembolism after major orthopaedic surgery. 19 July 2011. Available at: [Last accessed: July 2014].
  2. Daiichi Sankyo press release – Daiichi Sankyo Submits SAVAYSA™ (edoxaban) Tablets New Drug Application to the U.S. FDA for Once-Daily Use for Stroke Risk Reduction in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism. 9 January 2014. Available at: [Last accessed: September 2014].
  3. Daiichi Sankyo press release – Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism. 7 January 2014. Available at: [Last accessed: September 2014].
  4. Atrial fibrillation. Available at: Updated 2012. Last accessed August 2014.
  5. Ball J et al. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century. Int J Card 2013; 167:1807-1824.
  6. Camm A et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
  7. Go AS et al. Heart Disease and Stroke Statistics — 2013 Update: A Report From the American Heart Association. Circulation 2013; 127:6-245.
  8. Zimerman Ll et. al. Sociedade Brasileira de Cardiologia [Brazilian guidelines on atrial fibrillation]. Arq Bras Cardiol 2009;92:1-39.
  9. Inoue H et al. Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination. Int J Cardiol 2009 Oct 2;137(2):102-7.
  10. World Health Organization. The top 10 causes of death. July 2013. Available at: [Last accessed: July 2014].
  11. Lin H et al. Stroke severity in atrial fibrillation. Stroke 1996; 27:1760-1764
  12. Lamassa A et al. Characteristics, Outcome, and Care of Stroke Associated With Atrial Fibrillation in Europe.Stroke 2001; 32:392-398.
  13. Van Beek E et al. Deep vein thrombosis and pulmonary embolism. New York: John Wiley & Sons, 2009. Print.
  14. Bramlage P et al. Euro J of Clin Investigation 2005; 35 (Suppl. 1):4-11.
  15. Kunisawa S, Ikai H, Imanaka Y. Incidence and prevention of postoperative venous thromboembolism: are they meaningful quality indicators in Japanese health care settings? World J Surg. 2012; 36(2):280-6.
  16. Cohen A et al. Venous thromboembolism (VTE) in Europe. Thromb Haemost 2007; 98: 756–764.
  17. Deitelzweig S et al. Prevalence of venous thromboembolism in the USA: now and future. Thromb Haemost2009;7 (Suppl. 2):207-8 (abstract OC-WE-018).
  18. Heit JA et al., on behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. ASH Annual Meeting Abstracts. 106:910. 2005.
  19. Ogata K et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50:743-753.
  20. Buller H et al. Edoxaban versus Warfarin for the treatment of Symptomatic Venous Thromboembolism. N Engl J Med. 2013.
  21. Giugliano R et al. Edoxaban versus Warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-2104.
Source: Daiichi Sankyo

Written by asiafreshnews

September 29, 2014 at 2:46 pm

Posted in Uncategorized

DIAKRIT Launches the New Patent Pending D-Furnish(TM), a Furnishing Tool that Allows Home Buyers and Renters to Virtually Furnish Properties of Interest Online!

leave a comment »

-With the new D-Furnish™, decorating your new home or apartment has never been easier.

BANGKOK /PRNewswire/ — Considered the game-changer in the housing industry, D-Furnish™ revolutionizing the way property owners advertise online listing by allowing buyers and renters to virtually explore and experience the space and potential of a property as well as providing the tools to decorate the interior themselves.

D-Furnish is a patent pending, mobile-compatible online software that considerably enhances a property's potential by allowing clients to envision their perfect living space.
D-Furnish is a patent pending, mobile-compatible online software that considerably enhances a property’s potential by allowing clients to envision their perfect living space.

The new and improved D-Furnish™ features additions that greatly enhance the usability and practicality for the end user. These enhancements include:


Hundreds of furniture items are available, selected from the most popular items on the market today. Users are presented with the ability to explore new design ideas for their new home from the comfort of their current home.


In addition to the already vast array of decorative choices for the user, this new version of D-Furnish™ gives property owners the opportunity to partner with furniture suppliers and introduce custom furniture sets into the software, opening up ways to forge new partnerships with, and generate new revenue streams from, such suppliers while driving additional traffic to each online listing in the process.


Users can easily save their newly decorated home after they have furnished it and share it with family and friends alike.  The new print function allows the user to print out the selected furniture checklist so they don’t find themselves short of a vital piece of furniture when moving into their new home.


The new D-Furnish™ is built in HTML5, meaning it requires no plug-ins or app installations and is supported by both iOS and Android™ devices. Being fully mobile-compatible and responsive, it can be used on everything from smartphones to desktops, and from tablets to Smart TVs.

Try out the new D-Furnish™ by clicking on the demo link below:

You can also watch the product video by clicking on the link below:

About D-Furnish™

D-Furnish™ is a patent pending, mobile-compatible online software that considerably enhances a property’s potential by allowing clients to envision their perfect living space. With its cross-device compatibility and highly responsive design, buyers & renters can easily choose from a large variety of models to digitally furnish & decorate properties online.

The highly flexible interface also gives our customers the ability to incorporate & brand custom furniture sets and it drives additional revenue streams through 3rd party partnerships.


DIAKRIT’s mission is to revolutionize the real estate industry by offering its customers innovative digital solutions that enhance the end user experience.

Since its inception in 2001, DIAKRIT has grown rapidly and currently serves over 1,500 real estate clients worldwide. From cloud-based software, to 2D & 3D floor plan services, photo editing & retouching work, property slideshows, high-end 3D visualizations, flythrough animations and more, every product DIAKRIT develops and produces is specially designed to help make real estate professionals’ online listings attract more buyers & renters.

Thanks to its streamlined processes and in-house production, DIAKRIT is able to scale its business quickly to handle large volumes in record speed and at very affordable prices.  DIAKRIT is the global leader in 3D visualization products, digital sales applications and professional services for the real estate industry. DIAKRIT is currently represented in the United States, Sweden, Norway, Denmark and Thailand, has over 350 employees globally and more than 250 freelance photographers throughout Scandinavia.

For more information, please contact:

Matthew Campbell
Vice President & Head of Portal Sales
DIAKRIT International Ltd.

Archie Hong
+66 (0) 8-3071-5436

Photo –


Source: DIAKRIT International Ltd.

Written by asiafreshnews

September 29, 2014 at 2:38 pm

Posted in Uncategorized

EY reports 2014 global revenues of US$27.4b

leave a comment »

— Growth of 6.8% over FY2013 in local currency terms —
— Growth across all service lines; emerging markets practices grow 8.7% —
— Headcount at all-time high of 190,000 as EY ranked #1 world’s most attractive professional services employer, number #2 employer overall —
— Growth allows for continued investment in key markets, people and technology —

LONDON /PRNewswire/ — EY today announced combined global revenues of US$27.4b for its financial year ended 30 June 2014, a 6.8% increase over FY13 in local-currency terms. Revenues grew 6.0% in US dollar terms.

All of EY’s service lines continued to grow in FY14: Advisory grew 14.4%; Transaction Advisory Services grew 6.5%; Assurance grew 4.5%; and Tax grew 4.3%.

Mark Weinberger, EY’s Global Chairman and CEO, says:

“I am very proud of our people’s efforts, which resulted in another strong year of growth for EY. This follows our market-leading performance last year. This financial year began with the launch of the new EY brand under Vision 2020 – our plan to be the leading professional services organization by 2020. It finished with a set of accomplishments and results that show us moving from strength to strength.”

Revenue highlights by Area, market and sector
Across EY’s geographic Areas, the Americas enjoyed an increase of 9.1% on FY13. All other Areas – Europe,Middle East, India and Africa (EMEIA), Japan and Asia-Pacific – posted growth above 5% in local currency. EMEIA was buoyed by a 16.5% increase in India revenues. Despite weakening economic conditions in some regions, Asia-Pacific benefited from 6.8% revenue growth in Greater China.

EY’s emerging market practices grew by 8.7% overall, despite tough economic conditions and a slowdown in a number of key emerging market economies. This compares to 12% last year.

Weinberger says:

“Emerging markets will continue to drive economic growth for the foreseeable future. By 2020, we’re predicting about 30% of our revenue will be from emerging markets and we have earmarked US$1.5b for investment to support that growth.”

EY’s fastest growing sector practices were Life Sciences and Government and Public Sector, both of which saw double-digit revenue increases.

Weinberger says:

“Our success is about much more than our financial results, it’s also about our people and investments, which allow us to deliver exceptional, high-quality services all over the world.”

This year EY’s headcount grew to 190,000 people globally, an all-time high. For the second year in a row, EY has been voted the world’s most attractive professional services employer in the Universum World’s Most Attractive Employer poll of business students from top academic institutions in key markets globally. In the poll, EY is also the second most attractive employer of all businesses worldwide.

This year EY hired 60,000 people around the world, and invested half a billion US dollars on training to give its people the skills they need to deliver exceptional service for its clients.

Strong performance and confidence in the future led to 675 partner promotions. Along with 324 direct-admit partners, this was EY’s largest partner intake ever, with the largest number joining our Assurance practice. The new intake also is the most diverse ever, with a quarter of new partners from emerging markets, a quarter who have had mobility assignments outside of their native country, and 26% of them women, reflecting the importance placed on diverse, global experience in a world of increasing cross-border complexity.

Investing in the future
As well as investing in people and markets, EY is also investing across its service lines. These investments include:

  • Assurance: EY is making significant multi-year investments to transform the audit, to continuously improve audit quality and to fulfill stakeholder and public interest responsibilities. US$400m investments are being made in state-of-the-art audit technologies and processes to enhance audit quality and improve connectivity and collaboration.

Carmine Di Sibio, EY’s Global Managing Partner – Client Service, says:

“Investor confidence is the foundation of a strong global economy and sustainable audit quality is critical to that confidence. Auditors are being asked to do more to identify risk, have a forward-looking perspective and deliver high-quality results.

“We are making investments in process, people and technology, and combining this with advances in analytics to transform and increase the value and quality of the audit.”

  • Advisory: Advisory continues to grow organically, as well as through targeted acquisitions, to complement existing services and offerings. Substantial investments in digital, disruptive technologies and business analytics will further enhance Advisory’s ability to deliver transformational services to clients.
  • Transaction Advisory Services (TAS): For a fifth consecutive year TAS performance outpaced a subdued mergers and acquisitions market, as clients looked to EY for strategic investment advice on how they raise and manage their capital. The combination with global strategy consultants Parthenon underlines TAS’ investment in broader strategic services for FY15.
  • Tax: EY continues to invest in resources to help clients globally to comply with the ever-changing legislative and regulatory requirements impacting their businesses. Tax has strengthened and enhanced other services, including doubling the number of countries where it practices law. The strategic acquisition of Thomson Reuters’ Tax Preparation and Court Accounting Outsourcing businesses will enable EY to further expand tax offerings to financial services organizations.

Weinberger adds:

“These investments show the confidence that we have in EY’s future and in our clients’ businesses. We have more people, helping more clients, in more places than ever before – building a better working world through our people and our commitment to quality and exceptional client service.”

Supporting the next generation
As well as investing in its people and its business, as part of EY’s commitment to building a better working world, it is helping to tackle many issues important to our people, and economies around the world. One of those is the issue of youth unemployment – one of the most intractable social and economic challenges the world faces today. We tackle it through a strong internal commitment to developing future leaders and by supporting and collaborating with global initiatives in this field.

Weinberger says:

“We have many alliances and initiatives around the world to create opportunity and stimulate debate and solutions. For example, our membership of the Alliance for YOUth in Europe, our collaboration with the Clinton Global Initiative and relationships with Network for Teaching Entrepreneurship and Junior Achievement.”

Notes to editors

About EY
EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit

This news release has been issued by EYGM Limited, a member of the global EY organization that also does not provide any services to clients.

To watch Mark Weinberger discuss EY’s revenues and plans, please visit:

Tehira Taylor
EY Global Media Relations
+44 (0)20 7980 0703 / +44 (0)7920 577 549

EY FY14 revenues – selected information

EY revenues by service line – US$ millions



% Change



















Transactions Advisory Services










EY revenues by Area – US$ millions



% Change














Asia Pacific















EY people by service line



% Change













Transactions Advisory Services




Practice support








EY people by Area



% Change





















Basis of presentation

Revenues include expenses billed to clients. For purposes of reporting combined global revenues, revenues between member firms have been eliminated. Headcount numbers reflect personnel as of 30 June of each financial year.


Source: EY

Written by asiafreshnews

September 29, 2014 at 2:35 pm

Posted in Uncategorized

Darling Ingredients Inc. Announces New Appointment To Board Of Directors

leave a comment »

— Company Names Mary R. Korby as Director

IRVING, Texas /PRNewswire/ — Darling Ingredients Inc. (NYSE: DAR) today announced the appointment of Mary R. Korby to its Board of Directors. Ms. Korby joins the Board as an independent director, and her appointment is effective immediately.

The appointment of Ms. Korby will expand the total number of directors to eight. The Board of Directors has not yet determined the committees of the Board to which Ms. Korby will be appointed, if any.

Ms. Korby recently retired as a partner of the law firm of K&L Gates LLP, after having practiced law for more than 19 years as a partner at the law firms of K&L Gates LLP and previously, Weil Gotshal & Manges. During her legal practice, Ms. Korby advised boards of directors and companies regarding securities law compliance, stock exchange listings, disclosure issues and corporate governance, as well as tender offers, joint ventures and mergers and acquisitions, including complex cross-border public and private transactions in diverse industries such as chemicals, defense, recycling, green energy, aviation, and manufacturing.

“We are pleased to further strengthen our board with the appointment of an independent director who is a seasoned professional,” said Randall C. Stuewe, Chairman and CEO of Darling Ingredients.

About Darling

Darling Ingredients Inc. is the world’s largest publicly-traded developer and producer of sustainable natural ingredients from edible and inedible bio-nutrients, creating a wide range of ingredients and customized specialty solutions for customers in the pharmaceutical, food, pet food, feed, technical, fuel, bioenergy and fertilizer industries. With operations on five continents, the Company collects and transforms all aspects of animal by-product streams into useable and specialty ingredients, such as gelatin, edible fats, feed-grade fats, animal proteins and meals, plasma, pet food ingredients, organic fertilizers, yellow grease, fuel feedstocks, green energy, natural casings and hides. The Company also recovers and converts used cooking oil and commercial bakery residuals into valuable feed and fuel ingredients. In addition, the Company provides grease trap services to food service establishments, environmental services to food processors and sells restaurant cooking oil delivery and collection equipment. For additional information, visit the Company’s website at

{This media release contains “forward-looking” statements regarding the business operations and prospects of Darling Ingredients Inc. and industry factors affecting it. These statements are identified by words such as “believe,” “anticipate,” “expect,” “estimate,” “intend,” “could,” “may,” “will,” “should,” “planned,” “potential,” “continue,” “momentum,” and other words referring to events that may occur in the future. These statements reflect Darling Ingredient’s current view of future events and are based on its assessment of, and are subject to, a variety of risks and uncertainties beyond its control, each of which could cause actual results to differ materially from those indicated in the forward-looking statements. These factors include, among others, existing and unknown future limitations on the ability of the Company’s direct and indirect subsidiaries to upstream their profits to the Company for payments on the Company’s indebtedness or other purposes; general performance of the U.S. and global economies; disturbances in world financial, credit, commodities and stock markets; any decline in consumer confidence and discretionary spending, including the inability of consumers and companies to obtain credit due to lack of liquidity in the financial markets; volatile prices for natural gas and diesel fuel; climate conditions; unanticipated costs or operating problems related to the acquisition and integration of Rothsay and Darling Ingredients International (including transactional costs and integration of the new enterprise resource planning (ERP) system); global demands for bio-fuels and grain and oilseed commodities, which have exhibited volatility, and can impact the cost of feed for cattle, hogs and poultry, thus affecting available rendering feedstock and selling prices for the Company’s products; reductions in raw material volumes available to the Company due to weak margins in the meat production industry as a result of higher feed costs, reduced consumer demand or other factors, reduced volume from food service establishments, reduced demand for animal feed, or otherwise; reduced finished product prices; changes to worldwide government policies relating to renewable fuels and greenhouse gas emissions that adversely affect programs like the National Renewable Fuel Standard Program (RFS2) and tax credits for biofuels both in the U.S. and abroad; possible product recall resulting from developments relating to the discovery of unauthorized adulterations to food or food additives; the occurrence of Bird Flu including, but not limited to H1N1 flu, bovine spongiform encephalopathy (or “BSE”), porcine epidemic diarrhea (“PED”) or other diseases associated with animal origin in the U.S. or elsewhere; unanticipated costs and/or reductions in raw material volumes related to the Company’s compliance with the existing or unforeseen new U.S. or foreign regulations (including, without limitation, China) affecting the industries in which the Company operates or its value added products (including new or modified animal feed, Bird Flu, PED or BSE or similar or unanticipated regulations); risks associated with the renewable diesel plant in Norco, Louisiana owned and operated by a joint venture between Daring Ingredients and Valero Energy Corporation, including possible unanticipated operating disruptions; risks relating to possible third party claims of intellectual property infringement; increased contributions to the Company’s pension and benefit plans, including multiemployer and employer-sponsored defined benefit pension plans as required by legislation, regulation or other applicable U.S. or foreign law or resulting from a U.S. mass withdrawal event; bad debt write-offs; loss of or failure to obtain necessary permits and registrations; continued or escalated conflict in the Middle East, North Korea, Ukraine or elsewhere; and/or unfavorable export or import markets. Other risks and uncertainties regarding Darling Ingredients Inc., its business and the industries in which it operates are referenced from time to time in the Company’s filings with the Securities and Exchange Commission. Darling Ingredients Inc. is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.}


For More Information, contact:

Melissa A. Gaither, Director Investor Relations

251 O’Connor Ridge Blvd., Suite 300

Irving, Texas 75038

Phone: +1-972-717-0300

Source: Darling Ingredients Inc.

Related stocks: NYSE:DAR

Written by asiafreshnews

September 29, 2014 at 2:32 pm

Posted in Uncategorized